>> that's not my only complaint.
I actually tried not to be overly critical when I posted it. I couldn't believe what I read in PR, had to read call transcript to confirm the timeline given in PR was correct.
If they run a small earlier line trial, trying to explore more dosing regimens that might be different from later line trial because of so many possibilities, different flat low dose regimens, titration up regimen, titration down regimen, etc, sure. Now this big trial's enrollment will stretch to end of 2017 according to cc, it just doesn't make any sense to start it this year. Even IF 2nd line itself is a good idea - I don't think it is at this point - why not just wait for at least some data from the dose ranging trial? Why run such a big trial with very long duration to complete based on so little data?
News 
Market Data 
Discover 
AI
